Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02470702
Recruitment Status : Completed
First Posted : June 12, 2015
Last Update Posted : October 26, 2016
Sponsor:
Information provided by (Responsible Party):
The Medicines Company

Brief Summary:
This protocol describes a double-blind study to evaluate the safety and pharmacokinetics of multiple IV doses of 1200 mg ORBACTIV (oritavancin) in healthy subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: Oritavancin Drug: Placebo (D5W) Phase 1

Detailed Description:

Oritavancin has been approved in the United States for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs) caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms. The purpose of this study is to determine the (a) safety and tolerability and (b) pharmacokinetic profile of multiple doses of Oritavancin given over a 7-8 week period.

Cohort 1 will consist of 14 subjects, randomized to receive a total of four doses of either oritavancin or placebo, given once every two weeks in a double-blind fashion.

After completion of cohort 1, a Data Safety Monitoring Board will review the blinded safety data and pharmacokinetics (PK) for cohort 1 and determine whether to continue with cohort 2, modify cohort 2 or end the study. The cohorts for this study are sequential.

Cohort 2 will consist of 14 subjects, randomized to receive a total of eight doses of either oritavancin or placebo (4 subjects) given once every week in a double-blind fashion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: A Double-Blind Randomized Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple 1200 mg Dose Intravenous Oritavancin Infusions in Healthy Subjects
Study Start Date : June 2015
Actual Primary Completion Date : October 2015
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Oritavancin

Arm Intervention/treatment
Experimental: Oritavancin
Subjects randomized to oritavancin will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1200 mg oritavancin, infused intravenously over 3 hours
Drug: Oritavancin
Placebo Comparator: Placebo
Subjects randomized to placebo will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1000 mL D5W, infused intravenously over 3 hours
Drug: Placebo (D5W)



Primary Outcome Measures :
  1. Safety & Tolerability: AEs/SAEs [ Time Frame: From consent until day 110 safety follow up call ]
    a composite measure of the number and types of AEs/SAEs encountered and relationship to time of dosing

  2. Safety & Tolerability: clinical safety laboratory results [ Time Frame: From consent until day 110 safety follow up call ]
    A composite measure of multiple laboratory results assessing the clinical significance of any changes from baseline

  3. Safety & Tolerability: vital sign measurements [ Time Frame: From consent until day 110 safety follow up call ]
    A composite of multiple vital sign measurements, assessing the clinical significance of any changes from baseline

  4. Safety & Tolerability: ECGs [ Time Frame: From consent until day 110 safety follow up call ]
    A composite of multiple ECG measurements, assessing the clinical significance of any changes from baseline

  5. Safety & Tolerability: physical examination findings [ Time Frame: From consent until day 110 safety follow up call ]
    A composite of multiple physical examination findings, assessing the clinical significance of any changes from baseline


Secondary Outcome Measures :
  1. Pharmacokinetics: AUC0-last [ Time Frame: From pre-dose until 720 hours past last dose ]
    AUC from time zero to the time of the last measurable concentration

  2. Pharmacokinetics: AUC0-72 [ Time Frame: From pre-dose until 72 hours past last dose ]
    AUC from time zero to 72 hours post dose

  3. Pharmacokinetics: AUC0-∞ [ Time Frame: From pre-dose until 720 hours past last dose ]
    AUC from time zero to infinity

  4. Pharmacokinetics: Cmax [ Time Frame: From pre-dose until 720 hours past last dose ]
    maximum measured plasma concentration

  5. Pharmacokinetics: Cmin [ Time Frame: From pre-dose until 720 hours past last dose ]
    minimum plasma concentration

  6. Pharmacokinetics: Tmax [ Time Frame: From pre-dose until 720 hours past last dose ]
    time to Cmax

  7. Pharmacokinetics: t1/2 [ Time Frame: From pre-dose until 720 hours past last dose ]
    elimination half- life

  8. Pharmacokinetics: CL [ Time Frame: From pre-dose until 720 hours past last dose ]
    total body clearance

  9. Pharmacokinetics: VSS [ Time Frame: From pre-dose until 720 hours past last dose ]
    Volume of distribution



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject is able to provide written informed consent before initiation of any study-related procedures.
  2. Healthy male or female between the ages of 18 and 55 years, inclusive.
  3. Body mass index (BMI) < 45 kg/m2.
  4. Subject is in good health based on medical history and physical examination findings and has no clinically meaningful safety laboratory abnormalities (CBC, blood chemistry, and urinalysis) or 12 lead ECG results, as assessed by the PI.
  5. Vital signs (BP, pulse and temperature) measured at screening/baseline must be within the following ranges: SBP ≥90 to ≤150 mm Hg, DBP ≥45 to ≤90 mm Hg; Heart Rate ≥ 40 to ≤90 bpm (taken after resting in a supine position for at least 5 minutes).
  6. Willing to avoid all medications (other than the study drug and acetaminophen/paracetamol for minor aches/pains) during the study. This includes prescription and non-prescription medications, vitamins, herbal supplements, and nutriceuticals.
  7. Subject is a non-smoker and is willing to abstain from alcohol/illegal drug use for the duration of the study.
  8. If the female subject is surgically sterile, postmenopausal, or, if of childbearing potential, agrees to use at least 2 highly-effective methods of birth control (e.g. prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, barrier methods, abstinence) or male partner sterilization alone for the duration of the study until 60 days after study drug administration.

Exclusion Criteria:

  1. Has any condition, including findings in the medical history or in pre-study assessments that constitutes a risk or a contraindication for the participation in the study or completing the study.
  2. Female subjects of childbearing potential that have a positive test result for human chorionic gonadotropin (hCG) at screening.
  3. Female subjects who are nursing.
  4. Positive urine test for alcohol and/or for drugs of abuse at screening.
  5. Has a history or presence of alcohol/drug abuse within 2 years. Alcohol abuse is defined as regularly consuming >3 units/day (21 units per week for men), >2 units/day (14 units/week) for women. 1 unit of alcohol is defined as a can of 4% beer (330 mL), approximately 190 mL of 6-7% beer (malt liquor), a glass of 40% spirits (30 mL), or a glass of wine (100 mL).
  6. History of hypersensitivity to drugs with a similar chemical structure (i.e. glycopeptide antibiotics) to oritavancin or any of its excipients.
  7. Blood or plasma donation within the past 2 months.
  8. Subjects who participated in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days or 5 half-lives, whichever is longer, prior to screening and/or unwilling to allow at least two months before participation in another drug trial following the current trial.
  9. Treatment with any prescription or OTC drugs, within 2 weeks or 5 half-lives, whichever is longer, or herbal nutritional supplements within 2 weeks of screening, with the exception of acetaminophen/paracetamol for minor aches/pains. Subjects will not be allowed to receive medications for the duration of the study (except the above mentioned acetaminophen/paracetamol). Birth control or other hormone replacement is also permitted as long as it has been taken at a stable dose for at least three months before the screening visit and remains stable for the duration of the study.
  10. Males who are unwilling to practice abstinence or use an acceptable method of birth control during the entire study period (i.e. condom with spermicide).
  11. Subjects that have any surgical or medical condition that could interfere with the administration of the study drug.
  12. Subjects that have known active hepatitis B or C, or human immunodeficiency virus (HIV) infection or has known immune deficiency disease at screening.
  13. Subjects that have any condition that would confound or interfere with the assessment of safety.
  14. Subjects that have poor IV access as determined by the investigator. Subjects excluded for any of the previous criteria may only be rescreened for participation after discussion with sponsor and principal investigator.
  15. Prior exposure to Oritavancin alone or in combination with another product.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02470702


Locations
Layout table for location information
United States, Wisconsin
West Bend, Wisconsin, United States, 53095
Sponsors and Collaborators
The Medicines Company
Layout table for additonal information
Responsible Party: The Medicines Company
ClinicalTrials.gov Identifier: NCT02470702    
Other Study ID Numbers: MDCO-ORI-15-02
First Posted: June 12, 2015    Key Record Dates
Last Update Posted: October 26, 2016
Last Verified: October 2016
Keywords provided by The Medicines Company:
Volunteers
Additional relevant MeSH terms:
Layout table for MeSH terms
Oritavancin
Anti-Bacterial Agents
Anti-Infective Agents